Dr. Bill Latter examines Hershey, a Chocolate Labrador All Creatures Animal Clinic in Lakeland.

Buy Photo SCOTT WHEELER | THE LEDGER (2004) Published: Sunday, February 19, 2012 at 10:03 p.m. Last Modified: Sunday, February 19, 2012 at 10:03 p.m.

LAKELAND | William Latter, a Lakeland veterinarian, is one of 10 semifinalists for a national "Vet of the Year Award" given by a pet insurance provider.

Latter, founder and lead veterinarian at All Creatures Animal Clinic, is the only veterinarian from Florida on the list released by Petplan. The company's judging panel will narrow the list to three finalists later this month and name a winner in March, a spokeswoman said.

The semifinalists were chosen from nearly 2,000 veterinarians nominated by pet owners, the Petplan spokeswoman said.

Latter, 56, said he wasn't aware of the contest until learning he had been named a semifinalist. He has since learned he was nominated by a client who owns a miniature Schnauzer.

"I appreciate being included," Latter said. "I must admit when I heard a little remnant about it I thought, ‘Gosh, there are a lot of good vets out there doing a lot of good work,' and I wasn't sure even what the criteria was. I'm not sure I really felt I was qualified for such a thing."

The semifinalists were selected on the basis of their education and professional achievements and customer service, said Chris Ashton, Petplan's co-CEO. Ashton said the selection committee included four veterinarians.

Ashton said Petplan's sister company in Great Britain has held such a contest for about a decade, and this is the first year the provider has offered the award for veterinarians in the United States.

"It's a great way for us to recognize the veterinary profession," Ashton said by phone. "At the end of the day, we're a pet health insurance company. Our product is being used in veterinary clinics. (The award) is our way of giving back a little bit to recognize how great the veterinarians are."

Latter, a graduate of Michigan State University, opened All Creatures Animal Clinic in 1988. The South Lakeland practice includes one other veterinarian and a staff of 35.

Latter offers services not found at most veterinary clinics. He became certified in veterinary chiropractics in 1989 and does spinal manipulations on dogs.

"I started it because my own back was bothering me, and I decided to go to a chiropractor, myself ," Latter said. "That's what helped me to think it might be something for pets. It was new at that time. Now it's a little more mainstream than it used to be."

Latter's clinic also offers hydrotherapy and the use of laser stimulation of muscles. At one point, he also had a staff member who did acupuncture on animals.

Latter recently started offering stem-cell therapy for animals with chronic arthritis. He said his staff harvests stem cells from an animal's fatty deposits, generates a culture and then injects the cells into the targeted joints.

"New things are coming along all the time," Latter said. "It's kind of an exciting time to be veterinarian."

All Creatures also has a staff member who handles pet nutritional issues. Latter said the clinic has a kitchen in which food is prepared for pets with special dietary needs.

Latter and his wife of 36 years, Sue Latter, own two dogs, a golden retriever and a boxer.

Latter demonstrations an unusual level of dedication to the pets in his care, said Susan Gray, an employee at the clinic for 23 years.

"He has stayed late, gone to clients' homes and handled emergencies nights and weekends, countless times," Gray wrote in an email. "He continues to treat both his clients and his patients with utmost care and respect — always having a smile and a kind word for each."

The winner of the Petplan contest and one guest will be flown to Great Britain with all expenses paid to receive the award.

[ Gary White can be reached at gary.white@theledger.com or 863-802-7518. Join his discussion of books at http://www.facebook.com/ledgerlit. ]

Originally posted here:
Lakeland's Latter In Running For Award

EDMOND, OK--(Marketwire -02/19/12)- The team of veterinarians at White Oaks Veterinary Clinic in Edmond announced that the animal hospital is now offering pet stem cell therapy. This new regenerative medicine for pets helps animals suffering from degenerative joint disease or arthritis. Based on the research and technology provided by a company called Stemlogix, White Oaks Veterinary Clinic can now offer affordable, same-day stem cell therapy to dogs suffering from these debilitating conditions. The Stemlogix technology enables the Edmond veterinarians to extract adult stem cells from a pet's own body fat, virtually eliminating the risk of rejection or negative reaction.

"I see far too many otherwise healthy pets at our veterinary clinic that have been hobbled by the effects of arthritis," Dr. Jennifer Bianchi said. "We're thrilled to be able to offer this holistic solution which harnesses the pet's own healing power to aid in the pain relief process. Our main goal with stem cell therapy is to reduce long-term inflammation and slow the progression of cartilage damage. The motto at our veterinary hospital is, 'Quality service at a great value.' Being able to provide stem cell transplants in about two hours at an affordable rate helps us live up to that promise and makes me happy to think of the pets we'll be able to help move freely again."

The veterinary hospital now has an on-site stem cell laboratory for producing stem cells. The on-site lab allows for immediate processing after extraction as the stem cells have a limited lifespan outside of the pet's body. Once the fat cells have been procured from the pet, the stem cells are isolated and returned back to the host body within ninety minutes. Stemlogix promotes this therapy as being able to relieve pain and increase range of motion in pets suffering with joint pain, arthritis, tendon and ligament damage, hip dysplasia and cartilage damage.

Once implanted, stem cells have the ability to stimulate regeneration, reduce pain and inflammation, and assist in the repair of damaged tissue. They can also differentiate into other cell types such as tendon, cartilage, bone, and ligament, which may further aid the repair process. The Edmond veterinarian says that pain relief can be expected within a few days to a few weeks. Pet owners are cautioned to gradually allow their pets to experience increased activity so as not to interfere with the healing process.

As a holistic veterinarian, White Oaks Veterinary Clinic combines natural healing techniques, such as pet acupuncture, with traditional veterinary medical services. The animal hospital was founded in 1997 and is currently practicing out of a 6500 square foot facility. Equine vet, Dr. Mark Bianchi, offers general and advanced services such as surgery, equine dentistry, lameness evaluations and reproduction consultations.

White Oaks Veterinary Clinic is located at 131 W. Waterloo Rd. Further information on the animal hospital or pet stem cell therapy may be obtained by visiting the website at http://www.whiteoaksvet.com.

Link:
Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

MADISON, Wis., Feb. 16, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT.OB - News), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, announced that today its common stock will begin trading on OTCQX, the top tier of the OTC market designated for OTC companies that meet standards established by the OTC Market Group.  Novelos' trading symbol, "NVLT", will remain the same.  Investors may find current financial disclosure and Real-Time Level 2 quotes for Novelos via http://www.novelos.com or http://www.otcmarkets.com/stock/NVLT/quote.

"We are very pleased with this change of our quotation status to OTCQX," said Harry Palmin, President and CEO of Novelos.

"Novelos' transition to OTCQX from the OTCQB platform should enhance the trading experience for our shareholders, especially with the wider access to Real-Time Level 2 quotes," said J. Patrick Genn, Vice President of Investor Relations of Novelos.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM.PK - News) operates the world's largest OTC marketplace for equity securities.  OTC Markets Group's OTC Link® trading system delivers price transparency in over 10,000 securities and enables direct interaction between broker-dealers that provide liquidity and execution services.  OTC Markets Group organizes the marketplace by categorizing the wide spectrum of OTC-traded companies into three tiers: OTCQX® - The Intelligent Marketplace for the Best OTC Companies; OTCQB® - The Venture Marketplace; and OTC Pink® - The Open Marketplace.  OTC Markets Group's information-driven platform makes it easy for investors to trade at the best price through the broker of their choice and empowers companies to build the best markets for their investors.

About Novelos Therapeutics, Inc.

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our three cancer-targeted compounds are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  LIGHT is a small-molecule cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing.  HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as monotherapy for solid tumors with significant unmet medical need, subject to additional funding.  COLD, a cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition.  We plan to file an IND for COLD in the first quarter of 2013, subject to additional funding.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit http://www.novelos.com.

INVESTOR CONTACTS

J. Patrick Genn, Vice President of IR

Anne Marie Fields, Senior Vice President

Novelos Therapeutics, Inc.

Lippert/Heilshorn & Associates, Inc.

Ph: (858) 775-7456

Ph: (212) 838-3777      

Email: jpgenn@novelos.com

Email: afields@lhai.com

Novelos Therapeutics, Inc.

Madison, WI

Boston, MA

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

The rest is here:
Novelos Therapeutics to Begin Trading on OTCQX

NEW YORK, Feb. 16, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM.PK - News), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Novelos Therapeutics, Inc. (OTCQX: NVLT.OB - News), a U.S.-based pharmaceutical company, is now trading on the OTC market's highest tier, OTCQX®.

(Logo:  http://photos.prnewswire.com/prnh/20110118/MM31963LOGO&nbsp😉

Novelos began trading today on the OTC market's prestigious tier, OTCQX. U.S. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on http://www.otcmarkets.com.

"Investors prefer the quality-controlled admission process on OTCQX which identifies the segment of OTC companies focused on valuation and transparency," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Novelos Therapeutics to OTCQX."

Rodman & Renshaw, LLC will serve as Novelos' Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing guidance on OTCQX requirements.

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. (OTCQX: NVLT.OB - News) trades in the United States on OTCQX under the symbol "NVLT". Novelos Therapeutics is a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Novelos' three cancer-targeted compounds are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells.  Thus, Novelos' therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  LIGHT is a small-molecule cancer-targeted PET imaging agent.  Novelos believes that LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing.  HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells.  Novelos believes that HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and Novelos expects HOT to enter Phase 2 trials in the first quarter of 2013 as monotherapy for solid tumors with significant unmet medical need, subject to additional funding.  COLD, a cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition.  Novelos plans to file an IND for COLD in the first quarter of 2013, subject to additional funding.  Together, Novelos believes that its compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit http://www.novelos.com

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM.PK - News) operates the world's largest OTC marketplace for equity securities.  Our OTC Link® trading system delivers price transparency in over 10,000 securities and enables direct interaction between broker-dealers that provide liquidity and execution services.  We organize the marketplace by categorizing the wide spectrum of OTC-traded companies into three tiers: OTCQX - The Intelligent Marketplace for the Best OTC Companies; OTCQB® - The Venture Marketplace; and OTC Pink® - The Open Marketplace.  Our information-driven platform makes it easy for investors to trade at the best price through the broker of their choice and empowers companies to build the best markets for their investors.  To learn more about our Open, Transparent, and Connected marketplace, visit www.otcmarkets.com.

Subscribe to the OTCQX RSS Feed

Original post:
Novelos Therapeutics, Inc. Joins OTCQX

Just before 10 a.m. Tuesday, Jake — a hobbling, 12-year-old yellow Labrador retriever — went into surgery at the Stanley Veterinary Clinic in Overland Park with crippling arthritis, no longer able to run without pain or even walk down stairs.

He had already been on months of medications that seemed to turn the normally happy dog sad. And hip and joint replacements costing tens of thousands of dollars were not feasible, said owners Mike and Elizabeth LeBlanc of Leawood.Still, their 8-year-old daughter, Mia, had just one request at Christmas. “All I want is for Jake to feel better,” she wrote.So, on Tuesday morning, Jake became one of the first canines in the Kansas City area to undergo a somewhat new and controversial procedure in which stem cells were harvested from the fat of his own body and then injected into his joints. The expectation is that within a few weeks the cells will regenerate missing cartilage and turn his arthritic joints healthy again.“It’s amazing,” said veterinarian Les E. Pelfrey, who conducted the procedure. “A few weeks later, these guys are running up and down.”The stem-cell procedure, which has gained notice in recent years with anecdotal stories of success on YouTube and cable television, remains controversial not only for its quick adoption in veterinary clinics nationwide, but also because some researchers say it remains scientifically unproven and expensive, at $1,800 or more per treatment.“Let me tell you one thing,” said James L. Cook, a professor of orthopedics at the University of Missouri’s College of Veterinary Medicine. “I don’t want to write off stem cells. Stem cells may hold the key for truly restorative medicine.”In horses, stems cells have been shown to help rejuvenate damaged tendons and other problems. They are being tested for cardiac problems.“But in the joints for dogs with arthritis? No way,” Cook said. “I would never recommend anyone get this done.”Stem cells essentially are the equivalent of young and impressionable cells whose genetic gears have yet to determine their fate. Because they are so young, they theoretically can turn into any kind of cell, from cartilage to neurons. In humans, stem cells have long been held out as possible therapy for diseases such as Parkinson’s.The problem, Cook said, is that although a few studies have shown that the injection of stem cells into arthritic canine joints does reduce pain, compared with “control” dogs not injected with stems cells, no studies have convincingly shown that stems cells are any better at helping dogs than the current, and less expensive, standard of care. That typically involves a combination of weight loss, pain medications and, when necessary, injections of hyaluronic acid, a slippery substance that often goes missing in arthritis. Those injections, given a couple of times a year, cost less than $100 each.Moreover, even if the stem cells work, no one knows at this point how long the improvement will persist, although some vets have noted benefits lasting a year or more.“We know for sure that it (stem cell injections) does have some palliative effects. It can make symptoms better,” Cook said. “And we do know for sure that it does not regenerate cartilage in arthritic joints. The palliative effects are not as good, or no better, than hyaluronic acid injections.”That is far from the case being made by companies now promoting stem-cell therapy in dogs, or owners who believe in it.A number of stem-cell companies have emerged in recent years. Chief among them are Vet-Stem, based in Poway, Calif., and MediVet America, a division of MediVet, based in Sydney, Australia, which notes that it is currently conducting studies on canines, stem cells and cartilage regeneration.Both use largely similar technologies and methods. At the vet’s office, the dog undergoes a quick procedure in which a bolus of fat about the size of a golf ball is taken from above the shoulder.The fat is processed and treated with chemicals to extract millions of stem cells. Some of those cells are then injected into a dog’s damaged joints; the rest enter the body through an intravenous line into the bloodstream.One prime difference between the Vet-Stem and MediVet systems is that Vet-Stem costs about $3,000 or more.Vet-Stem requires the veterinarian to ship the fat sample to California, where it is processed and sent back for injection. Several dogs in the Kansas City area have been injected with stem cells from Vet-Stem.The MediVet system costs pet owners about $1,800. It provides veterinarians with a kit to process the stem cells in their own offices over about four hours. Dogs are injected with stems cells on the same day the fat is removed. The pet typically goes home the next day.In Topeka, the University Bird and Small Animal Clinic has used the MediVet kit and system with what it says are positive results on about 40 dogs since November 2010. A veterinarian there, Larry Snyder, helped train Pelfrey in Overland Park.Snyder came to the clinic two weeks ago to perform the procedure on another hobbled yellow Labrador retriever, Milo, owned by dentist Jon Finley and his wife, Sharon, in Leawood.“Dr. Pelfrey and Mrs. Finley didn’t tell me how much this procedure was going to cost,” Jon Finley said, “and I’d rather you not tell me. No matter what, he’s walking better, standing upright, feeling better. I can’t help but think he’s going to get better and better.”Jake’s owner said that, whatever the outcome, she knows that the procedure is not a cure.“I’m hoping this gives him a better quality of life,” Elizabeth LeBlanc said. “I got him when he was just 6 weeks old. He was such a blessing. It will be worth it, even if I can give him one more great summer.”

To reach Eric Adler, call 816-234-4431 or send email to eadler@kcstar.com.

Excerpt from:
First local dogs receive ‘amazing’ stem-cell therapy

MADISON, WI--(Marketwire -02/06/12)- Novelos Therapeutics, Inc. (OTC.BB: NVLT.OB - News), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012. Mr. Palmin is scheduled to present at 4pm EST in the Duke of Windsor Suite on the 4th floor. The event will be held February 13-14 at The Waldorf Astoria in New York City.

A live webcast of the Novelos presentation may be accessed via http://www.novelos.com
The webcast will be archived for 90 days following the presentation.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Information about the conference is available at http://www.bio.org/events/conferences/14th-annual-bio-ceo-investor-conference

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our three cancer-targeted compounds are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. LIGHT is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing. HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as monotherapy for solid tumors with significant unmet medical need. COLD, a cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. We plan to file an IND for COLD in the first quarter of 2013. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Continued here:
Novelos Therapeutics to Present at the 14th Annual Bio CEO & Investor Conference on February 13

Do you remember when we used to think some things were impossible? Modern technology has taught us to never say never or impossible. I think about the 1970s and 1980s growing up without cell phones, computers and many of the electronically advanced gadgets that our kids today take for granted. I can’t even imagine what the great innovators will come up with next.

When I was a young child, I remember watching science fiction movies about cloning people and remember how obscure and unbelievable it seemed at the time. It was common knowledge that cloning was strictly science fiction. Now, cloning is not only possible, but a procedure that has occurred with astonishing success. Fortunately, cloning has only been performed with animals and not yet humans.

Medically speaking, one of the most popular and potentially one of the most substantial advances in modern medicine is stem cell research and therapy. Initially, stem cell research was met with a great deal of resistance and controversy. The reason stem cell research had trouble getting started was because stem cells could only be collected from fetuses. With time, scientists have successfully harvested stem cells from other sources.

Stem cells are primitive or extremely young cells which are capable of dividing and changing into a variety of cell types. They have the ability to develop into cells that form muscle, cartilage, bone or other tissues. One of the remarkable findings about stem cells is that they seem to detect and “know” which tissue is damaged and automatically change into the cells needing repaired.

In actuality, the damaged tissue sends some type of signal to the stem cells allowing them to respond and promote healing of the injured tissues. Essentially, stem cells have the ability to grow into mature tissue cells wherever they are needed and this makes them very useful for repairing certain body tissues damaged by injury, disease and possibly aging.

Stem cell treatment is a type of medical therapy called regenerative medicine. Regenerative medicine is simply a category of medical therapy pertaining to growing new tissue. Although stem cell therapy is an extremely unique and obviously beneficial type of medical treatment, it is also a very vast field of medical research and certainly has not been completely perfected. There are countless possibilities and applications for stem cell therapy and medical researchers have barely scratched the surface with regards to stem cell potential.

Until now the gold standard for treating arthritis in pets has been to give them anti-inflammatory medications, joint supplements and sometimes acupuncture. Over the years, these types of medications have improved greatly and pets have benefitted wonderfully from receiving this kind of treatment. However, even with the improvements, these medications have potential side effects. Sometimes, the side effects may even outweigh the benefits, depending on the individual circumstance.

Therefore, stem cell therapy offers treatment that doesn’t just relieve the symptoms, but actually regenerates or grows new tissue allowing for complete healing and without side effects. Presently, there are some stem cell applications already being used in veterinary medicine!

Recently, veterinary specialists have developed a technique for collecting stem cells from fat tissue and administering the stem cells into dogs, cats and horses specifically for treatment of arthritis. The process involves collecting a small amount of fat from the patient and then the fat is placed into a machine which extracts and concentrates stem cells. Next, the stem cells are injected back into the patient’s joints forthe treatment of arthritis.

There is a certain protocol for proceeding with the stem cell therapy. First, a definitive diagnosis of arthritis, using X-rays, must be made by your veterinarian. Additionally, your pet would need a complete workup including blood tests and additional X-rays to rule out any other disease processes such as infection or cancer. Any patient with cancer would not be a good candidate for stem cell therapy and any infection would need to be cleared prior to stem cell therapy.

Following the initial workup, your pet would be sedated or anesthetized for surgical collection of fat tissue. The fat tissue would then be sent to a lab to have the stem cells extracted and processed from the fat. Then, your pet would need to be sedated again to administer the injections containing the stem cells into their arthritic joints.

In pets, stem cell therapy is primarily available and being used for arthritis. However, I have no doubt that it won’t be long before stem cell therapy will be used in pets to treat many diseases and conditions. It has already shown to be effective for diabetes, allergies, gastrointestinal diseases, pancreatitis and many other diseases.

If you have a pet that you think might be suffering from arthritis, contact your veterinarian as soon as possible to consider stem cell therapy and to ensure your pet lives a long, healthy and happy life.

Excerpt from:
The Pet Corner: Behold! The future of modern medicine is here

Home > News > health-news

Washington, Jan 10 : Stem cells of cord blood can be used to treat Type 1 diabetes, a new study has revealed.

Type 1 diabetes is caused by the body's own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient's blood glucose levels.

A new method described in the new study uses stem cells from cord blood (blood that remains in the placenta and in the attached umbilical cord after childbirth) to re-educate a diabetic's own T cells and consequently restart pancreatic function reducing the need for insulin.

Stem Cell Educator therapy slowly passes lymphocytes separated from a patient's blood over immobilized cord blood stem cells (CBSC) from healthy donors.

After two to three hours in the device the re-educated lymphocytes are returned to the patient.

The progress of the patients was checked at 4, 12, 24 and 40 weeks after therapy.

C-peptide is a protein fragment made as a by-product of insulin manufacture and can be used to determine how well beta cells are working.

By 12 weeks after treatment all the patients who received the therapy had improved levels of C ?peptide. This continued to improve at 24 weeks and was maintained to the end of the study.

This meant that the daily dose of insulin required to maintain their blood glucose levels could be reduced. In accordance with these results the glycated hemoglobin (HbA1C) indicator of long term glucose control also dropped for people receiving the treatment, but not the control group.

"We also saw an improved autoimmune control in these patients," Dr Yong Zhao, from University of Illinois at Chicago, who led the multi-centre research, said.

Stem Cell Educator therapy increased the percentage of regulatory T lymphocytes in the blood of people in the treatment group. Other markers of immune function, such as TGF-beta1 also improved.

The study has been published in BioMed Central's open access journal BMC Medicine. (ANI)

Share this article at

Yearly Horoscope of 2012 for the Zodiac Sign:

Sagittarius     Scorpio     Libra    Virgo    Leo     Cancer     Gemini     Taurus     Aries     Pisces     Aquarius     Capricon

TOP READ ARTICLES:

Gary Glitter could earn thousands of pounds from Super Bowl royalties
Keira Knightley overcame dyslexia by reading Emma Thompson's film script
Demi Lovato says she lacks confidence to face camera
Demi Moore taking 'spiritual counselling' after hospitalisation
Tilda Swinton lets her friends choose her red carpet dresses
Nicola Roberts furious over Girls Aloud break
Rooney Mara to star in 'Side Effects'
Reese Witherspoon impressed with Robert Pattinson
Simon Cowell to air backstage drama on 'Britain's Got Talent'
Patrick Stewart regrets putting career over family
Rachel McAdams shocked by Tatum's fake penis
Cynthia Nixon clarifies remark about being gay by choice
George Clooney said 'I Love You' to Mary Tyler Moore
Elton John advises Madonna to 'lip-synch good' at Super Bowl gig
'The Artist' dog star Uggie to retire from films

More here:
Stem cell treatment may help reverse diabetes

See the article here:
Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

23-12-2011 09:16 http://www.franchise.com presents - Medivet America Pet Franchise provides innovative, and now affordable, therapy for pets suffering from conditions like arthritis. Using stem cell regenerative therapy treatment Medivet is able to using stem cells, meant for repairing the body, to target and treat your pets conditions. veterinarian

Go here to see the original:
Medivet America Pet - Video